On July 9, Alebund Pharmaceuticals-B declined 5.4% in regular trading, trading at approximately 31.4 HKD/share, with turnover of HKD 2.91 million. The pullback follows the previous session's sharp rally of over 10%, which was driven by news that GIC and LAV collectively increased their holdings by over 1.32 million shares on the IPO date, involving approximately HKD 59 million in capital.

GIC acquired 872,000 shares at HKD 44.08 per share, raising its stake to 7.09%, while LAV purchased 450,000 shares at HKD 45.06, bringing its holding to 7.20%. Today's retreat is interpreted as short-term profit-taking after the institutional-buying-fueled surge. Since its June 29 listing at an IPO price of HKD 22.6, the stock has experienced extreme volatility, surging over 103% on its debut before undergoing multiple rounds of sharp swings.

The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301 is in the NDA sprint stage, with a China new drug application expected imminently and commercialization anticipated within 12 to 24 months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)